BELLEVILLE, Ontario, June 27 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced that Cameron Groome is joining its management team as Executive Vice-President, Corporate & Strategic Development.
Mr. Groome joins Bioniche from a major Canadian investment dealer, where he led its life sciences investment banking activities. He is well-known to Canadian life sciences companies and investors, having had success as an equity analyst, industry commentator, investment banker and corporate advisor. Mr. Groome’s experience is comprised of more than 15 years focused on life sciences and includes more than 100 successful capital market and other business transactions for firms in the sector.
“Cameron is a great addition to our Executive team,” said Graeme McRae, President and CEO of Bioniche Life Sciences Inc. “He has a broad knowledge of science, biotechnology, health services, and capital markets, all of which will contribute to our strategy for corporate growth. Cameron has recently advised Bioniche on two major transactions, and has consulted on others, demonstrating his skill set first-hand to the Company. We are pleased to have him join us at such an important time in our development - with our proprietary treatment for bladder cancer now entering Phase III clinical trials with fast track status and our proprietary E. coli O157:H7 cattle vaccine in the U.S. regulatory pathway. As these projects near completion, the Company looks forward to continuing to develop its rich pipeline, and Cameron will play a key role in this.”
Added Cameron, “After so often acting as an outside advisor, it is a pleasure to be accorded an executive position with so promising a firm. I welcome the opportunity to become part of a very talented team and help drive the creation of lasting value.”
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 185 skilled personnel and has three principal operating divisions: Human Health, Animal Health, and Food Safety. The Company’s primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit http://www.Bioniche.com.
Except for historical information, this news release may contain forward- looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
For further information, please contact: Jennifer Shea Manager of Corporate Communications & Investor Relations Bioniche Life Sciences Inc. Telephone: (613) 966-8058 ext. 1250 Cell: (613) 391-2097
Bioniche Life Sciences Inc.
CONTACT: Jennifer Shea, Manager of Corporate Communications & InvestorRelations of Bioniche Life Sciences Inc., +1-613-966-8058 ext. 1250, orCell: +1-613-391-2097
Web site: http://www.bioniche.com/
